版本:
中国

BRIEF-Roche receives FDA approval for complementary PD-L1 (SP263) biomarker test in Urothelial Carcinoma

May 2 Roche Holding Ag :

* Roche receives FDA approval for complementary PD-L1 (SP263) biomarker test in Urothelial Carcinoma

* Continues to pursue regulatory approval for Ventana PD-L1 (SP263) assay in other cancer indications in US and in other geographies Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐